← Eichor
Study identifier: NCT07179276 Synced from ClinicalTrials.gov · July 29, 2026
● Recruiting

Veno-arterial Carbon Dioxide Partial Pressure Difference (CO2gap) for Early Resuscitation of Septic Shock

Condition: Sepsis - to Reduce Mortality in the Intensive Care Unit · Septic Shock  ·  Sponsor: University Hospital, Clermont-Ferrand

PhaseNA
Planned participants750
Who can joinAll sexes, 18 Years to no upper limit
Healthy volunteersNo

About this study

Sepsis is a dysregulated host response to infection that leads to life-threatening organ dysfunction and represents a major healthcare problem. Septic shock is the most severe form, characterized by increased capillary permeability and vasodilation, resulting in hypotension and tissue hypoxia. Early identification and treatment of tissue hypoperfusion are pivotal components of initial resuscitation to limit progression to multiple organ dysfunction and death. The 2021 Surviving Sepsis Guidelines recommend guiding initial resuscitation by targeting decreases in serum lactate levels in patients with elevated lactate. However, although elevated lactate levels may reflect tissue hypoxia, serum lactate is not a direct marker of tissue perfusion. Hyperlactatemia may be attributable to mechanisms other than tissue hypoperfusion, such as accelerated aerobic glycolysis driven by excessive β-adrenergic stimulation or impaired clearance (e.g., in liver failure). The venous-to-arterial carbon dioxide partial pressure difference (CO₂ gap), which is inversely related to cardiac output, has been shown to reflect the adequacy of venous blood flow to remove CO₂ from tissues. The CO₂ gap is closely linked to microcirculatory blood flow during the early resuscitation phase of septic shock and may effectively identify persistent tissue hypoperfusion in shock states. A persistently high CO₂ gap during early resuscitation has been associated with significantly higher 28-day mortality and increase…

This description comes directly from the study's public registry record.

Talk to the study team

Lise Laclautre  ·  0473754963  ·  promo_interne_drci@chu-clermontferrand.fr

Always discuss trial participation with your own doctor first.

Locations (28)

CHu AngersAngers, FranceNot Yet Recruiting
CH AurillacAurillac, FranceNot Yet Recruiting
CH de la Côte BasqueBayonne, FranceRecruiting
CHU Bordeaux Hôpital Haut LévèqueBordeaux, FranceRecruiting
CHU Bordeaux Pellegrin HospitalBordeaux, FranceRecruiting
CHU Clermont-Ferrand EstaingClermont-Ferrand, FranceRecruiting
CHU Clermont-Ferrand Gabriel MontpiedClermont-Ferrand, FranceRecruiting
CHU DijonDijon, FranceRecruiting
CHU GrenobleGrenoble, FranceNot Yet Recruiting
CH Le puy en VelayLe Puy-en-Velay, FranceRecruiting
HCL - Lyon SudLyon, FranceNot Yet Recruiting
HCL Hôpital Edouard HerriotLyon, FranceNot Yet Recruiting

+ 16 more locations — full list on the registry record.

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT07179276